{"id":"W7116801625","doi":"10.1158/1078-0432.ccr-25-2239","title":"Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non–Hodgkin Lymphoma (CAPITAL)","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Kite Pharma; Astex Pharmaceuticals; BeiGene; Gilead Sciences; AstraZeneca; Eli Lilly and Company","keywords":"Refractory (planetary science); Lymphoma; Limiting; Cancer; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009317589,0.0003494999,0.0006837786,0.0002096459,0.0001684633,0.0004752204,0.0002615472,0.0003480935,0.001413457],"category_scores_gemma":[0.0007616008,0.0002054362,0.000469084,0.0002008873,0.0003749539,0.0004082188,0.000176781,0.0009600047,0.0002945485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005545164,"about_ca_system_score_gemma":0.0005258667,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004493559,"about_ca_topic_score_gemma":0.001100787,"domain_scores_codex":[0.9997132,0.0001175777,0.00003019397,0.000054069,0.00005116417,0.00003375845],"domain_scores_gemma":[0.9996672,0.00007693156,0.00009468303,0.00002903249,0.00002865094,0.0001035373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3417829,0.0121853,0.1367468,0.001242523,0.001970526,0.0007262334,0.0005065291,0.004489826,0.08451286,0.0002501422,0.005971141,0.4096152],"study_design_scores_gemma":[0.122682,0.4714578,0.3600459,0.0001650218,0.001926768,0.002117716,0.0002323896,0.006234969,0.02320985,0.0002644581,0.01159597,0.00006721855],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950027,0.00294732,0.0001426809,0.0001178358,0.00002134279,0.0001802567,0.000401562,0.00002905514,0.001157311],"genre_scores_gemma":[0.9982309,0.0005637204,0.0001651642,0.0001484266,0.0000352761,0.00007426496,0.0004183476,0.000003444557,0.0003604661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001413457,"threshold_uncertainty_score":0.004927635,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0427337186662007,"score_gpt":0.4066724772703794,"score_spread":0.3639387586041787,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}